The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment Effect and Response (MAKE BETTER) Study: Design and Methodology

Objective Depression is associated with a major disease burden, and many individuals suffer from depressive symptoms due to an insufficient response to ostensibly adequate antidepressant treatment. Therefore, it is important to identify reliable treatment response predictors for use in developing personalized treatment strategies. Methods The MAKE Biomarker discovery for Enhancing anTidepressant Treatment Effect and Response (MAKE BETTER) study was performed to identify predictors of antidepressant response using a 2-year naturalistic prospective design. Participants in the MAKE BETTER study were consecutively recruited from patients who visited the Psychiatry Department of Chonnam National University Hospital, Gwangju, South Korea for treatment of a depressive disorder. Data on demographic and clinical characteristics, genetic markers measured by whole-exome sequencing, and blood markers were obtained. The types and doses of antidepressants were determined based on the clinical judgment of the psychiatrist, and the treatment outcomes (e.g., depressive and other psychiatric symptoms and issues related to safety) were assessed. Results We will be able to use the data collected in this study to develop a treatment-response prediction index composed of biomarkers. Conclusion The MAKE BETTER study will provide an empirical basis for a personalized medicine approach to depression by enabling the prediction of antidepressant treatment response according the characteristics of each patient. It will thereby support evidencebased decision-making that decreases the use of a trial-and-error approach to the treatment of depressive disorders.

• Publication year

  2018

• Venue

  Psychiatry Investigation

• Publication date

  2018-04-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.30773/pi.2017.10.2PMID 31630503PMCID 6801320
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A New Prediction Model for Evaluating Treatment-Resistant Depression.

  2017cited by this paper
• Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder

  2016cited by this paper
• Pharmacogenetics of antidepressant response: a polygenic approach

  2016cited by this paper
• BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis.

  2015cited by this paper
• Clinically Useful Genetic Markers of Antidepressant Response: How Do We Get There From Here?

  2015cited by this paper
• Longitudinal effects of the SSRI paroxetine on salivary cortisol in Major Depressive Disorder.

  2015cited by this paper
• A genome-wide association study of antidepressant response in Koreans

  2015cited by this paper
• Inflammation and clinical response to treatment in depression: A meta-analysis.

  2015cited by this paper
• The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response

  2015cited by this paper
• Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis

  2014cited by this paper
• Increased cortisol awakening response was associated with time to recurrence of major depressive disorder.

  2014cited by this paper
• Diagnostic and Statistical Manual of Mental Disorders

  2013cited by this paper
• Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.

  2013cited by this paper
• CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies.

  2013cited by this paper
• Contribution of common genetic variants to antidepressant response.

  2013cited by this paper
• Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression

  2013cited by this paper
• Possible association of CUX1 gene polymorphisms with antidepressant response in major depressive disorder

  2012cited by this paper
• Lower cortisol levels predict recurrence in remitted patients with recurrent depression: a 5.5 year prospective study.

  2012cited by this paper
• Longitudinal hypothalamic-pituitary-adrenal axis trait and state effects in recurrent depression.

  2012cited by this paper
• Treatment-resistant depression: therapeutic trends, challenges, and future directions

  2012cited by this paper
• Approaches to Understanding and Addressing Treatment-Resistant Depression: A Scoping Review

  2012cited by this paper
• A GLOBAL MEASURE OF PERCEIVED STRESS

  2012cited by this paper
• Multidimensional Scale of Perceived Social Support

  2011cited by this paper
• Serum BDNF levels before treatment predict SSRI response in depression.

  2011cited by this paper
• The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis

  2011cited by this paper
• A genomewide association study of citalopram response in major depressive disorder.

  2010cited by this paper
• Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.

  2010cited by this paper
• Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder

  2010cited by this paper
• The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders.

  2009cited by this paper
• Associations between sociodemographic, sampling and health factors and various salivary cortisol indicators in a large sample without psychopathology.

  2009cited by this paper
• A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression.

  2009cited by this paper
• Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-Analysis

  2009cited by this paper
• Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management.

  2009cited by this paper
• How can we realize the promise of personalized antidepressant medicines?

  2008cited by this paper
• Current trends in the assessment and somatic treatment of resistant/refractory major depression: An overview

  2008cited by this paper
• A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression.

  2008cited by this paper
• The Assessment of Poststroke Depression

  2007cited by this paper
• Measuring personality in one minute or less: A 10-item short version of the Big Five Inventory in English and German

  2007cited by this paper
• Medication augmentation after the failure of SSRIs for depression.

  2006influential reference
• Development of a new resilience scale: The Connor‐Davidson Resilience Scale (CD‐RISC)

  2003cited by this paper
• Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 2nd ed.

  2002cited by this paper
• Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy.

  2001cited by this paper
• EQ-SD: a measure of health status from the EuroQol Group

  2001cited by this paper
• The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

  1998cited by this paper
• The Hospital Anxiety and Depression Scale.

  1987cited by this paper
• The Anxiety Disease

  1984cited by this paper
• A diagnostic interview: the schedule for affective disorders and schizophrenia.

  1978cited by this paper
• The Brief Psychiatric Rating Scale

  1962cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Personality moderates the predictive value of serum serotonin for antidepressant remission in depressive disorders.

  2026cites this paper
• Interactive dynamic modulation of antidepressant treatment response by serum interleukin-1β and Neuroticism at 12 weeks

  2026cites this paper
• Employment-dependent associations of serum biomarkers with short- and long-term antidepressant treatment outcomes

  2026cites this paper
• Neurochemical biomarkers in major depressive disorder.

  2026cites this paper
• Multimodal machine learning models for predicting remission in major depressive disorder using clinical data, blood biomarkers, and DNA methylation.

  2026cites this paper
• Prediction of 12-Week Remission in Patients With Depressive Disorder Using Reasoning-Based Large Language Models: Model Development and Validation Study

  2026cites this paper
• Prospective Associations of Serum Tumor Necrosis Factor-Alpha and Employment on Suicidal Behaviors Over 1 Year in Depressive Patients Receiving Psychopharmacotherapy

  2025cites this paper
• Exploring the prospective association of serum interleukin-1β and brain-derived neurotrophic factor with antidepressant treatment response.

  2025cites this paper
• Serum multi-biomarkers for predicting relapse in patients with depressive disorders under psychopharmacotherapy.

  2025cites this paper
• Cross-sectional and longitudinal analysis of high-sensitivity C-reactive protein as a biomarker for suicidal behavior in depressive patients undergoing pharmacotherapy.

  2025cites this paper
• Exploring the combined effects of serum tumor necrosis factor-alpha and serotonin on antidepressant efficacy in depression: A 12-week prospective analysis.

  2025cites this paper
• Childhood abuse moderates the impact of serum BDNF on short- and long-term antidepressant response.

  2025cites this paper
• Exploring the combined influence of serum serotonin and brain-derived neurotrophic factor on depression remission: Short- and long-term responses.

  2025cites this paper
• Interaction between ghrelin and social support predicts antidepressant treatment outcomes in patients with depression.

  2025cites this paper
• Functional status modifies the impact of tumor necrosis factor-alpha on depression treatment response

  2025cites this paper
• Inflammation-neurotrophin interplay and depression outcomes: authors' reply.

  2025cites this paper
• Interaction Effect of Childhood Abuse History and Suicidality on 12-Month Antidepressant Response in Patients With Depressive Disorder

  2024cites this paper
• Enhancing predictive accuracy for antidepressant response in depressive disorders: The additive value of interleukin-1β and interleukin-6 alongside hsCRP.

  2024cites this paper
• Interplay between Stressful Life Events and Interleukin-1β on 12-week Antidepressant Response in Depressive Patients

  2024cites this paper
• Editorial: Biomarkers of mental well-being continuum across life span: from excelling to crisis

  2024cites this paper
• Age-specific associations between inflammatory markers and remission of depression during antidepressant use.

  2023cites this paper
• Age-specific associations between serum cholesterol levels and suicidal behaviors in patients with depressive disorders: A naturalistic prospective observational cohort study

  2023cites this paper
• Multiple serum biomarkers for predicting suicidal behaviours in depressive patients receiving pharmacotherapy

  2023cites this paper
• Childhood Abuse, Social Support, and Long-Term Pharmacological Treatment Outcomes in Patients With Depressive Disorders

  2022cites this paper
• Interactive Effects of Serum Leptin Levels and Physical Comorbidity on the Pharmacotherapeutic Response of Depressive Disorders

  2022cites this paper
• Prospective associations of multimodal serum biomarkers with 12-week and 12-month remission in patients with depressive disorders receiving stepwise psychopharmacotherapy.

  2022cites this paper
• Multiple serum biomarkers for predicting suicidal behaviours in depressive patients receiving pharmacotherapy

  2022cites this paper
• Prediction of 12-Week Remission by Psychopharmacological Treatment Step in Patients With Depressive Disorders

  2022cites this paper
• Interaction effect between childhood abuse and interleukin-1β levels on suicidality in depressed patients

  2022cites this paper
• Associations of Serum Serotonin Levels with 12-week and 12-month Remission in Patients with Depressive Disorders

  2022cites this paper
• Interaction effect of the serum interleukin-6 level and anxiety on the 12-week pharmacotherapeutic responses of patients with depressive disorders.

  2022cites this paper
• Predictors of Remission in Acute and Continuation Treatment of Depressive Disorders

  2021cites this paper
• Prediction of Suicidality According to Serum Folate Levels in Depressive Patients Receiving Stepwise Pharmacotherapy

  2021cites this paper
• Interaction effect of serum serotonin level and age on the 12-week pharmacotherapeutic response in patients with depressive disorders

  2021cites this paper
• Associations of serum cortisol levels, stress perception, and stressful events with suicidal behaviors in patients with depressive disorders.

  2021cites this paper
• Synergistic effects of resilience and serum ghrelin levels on the 12-week pharmacotherapeutic response in patients with depressive disorders.

  2021cites this paper
• Investigating associations of childhood abuse and serum brain-derived neurotrophic factor levels with suicidal behaviours in patients with depressive disorders

  2021cites this paper
• Predictive values of tumor necrosis factor-α for depression treatment outcomes: effect modification by hazardous alcohol consumption

  2021cites this paper
• Interactive effects of systemic inflammation and life stressors on treatment response of depressive disorders.

  2021cites this paper
• Sex differences in the genetic architecture of depression

  2020cites this paper
• Short and long-term treatment outcomes of stepwise psychopharmacotherapy based on early clinical decision in patients with depressive disorders.

  2020cites this paper
• Genetic markers for depressive disorders with earlier age at onset.

  2020cites this paper
• Genetic Markers for Later Remission in Response to Early Improvement of Antidepressants

  2020cites this paper
• Standardization of the Discrimination and Stigma Scale-Korean Version (DISC 12-K) in Patients with Depressive Disorders

  2020cites this paper
• Neurogenesis and antidepressant action

  2019cites this paper